Johnson and Johnson: Rybrevant Plus Lacluze Shows Statistically Significant and Clinically Meaningful Improvement in Overall Survival Versus Osimertinib
January 08, 2025
January 08, 2025
NEW BRUNSWICK, New Jersey, Jan. 8 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
Median overall survival improvement expected to exceed one year
First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
* * *
RARITAN, N.J., January 7, 2025 - Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard . . .
* * *
Median overall survival improvement expected to exceed one year
First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
* * *
RARITAN, N.J., January 7, 2025 - Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard . . .